Early diagnosis, clinical management, and follow-up of cardiovascular events with ponatinib-Reference-Cited by-同舟云学术

Early diagnosis, clinical management, and follow-up of cardiovascular events with ponatinib

Published:2020-02-05 Issue:3 Volume:25 Page:447-456
ISSN:1382-4147
Container-title:Heart Failure Reviews
language:en
Short-container-title:Heart Fail Rev

Author:

Casavecchia Grazia,Galderisi Maurizio,Novo Giuseppina,Gravina Matteo,Santoro Ciro,Agricola Eustachio,Capalbo Silvana,Zicchino Stefano,Cameli Matteo,De Gennaro Luisa,Righini Francesca Maria,Monte Ines,Tocchetti Carlo Gabriele,Brunetti Natale Daniele^ORCID,Cadeddu Cristian,Mercuro Giuseppe

Publisher

Springer Science and Business Media LLC

Subject

Cardiology and Cardiovascular Medicine

Link

http://link.springer.com/content/pdf/10.1007/s10741-020-09926-y.pdf

Reference48 articles.

1. Melo JV (1996) The molecular biology of chronic myeloid leukaemia. Leukemia. 10:751–756

2. Cortes JE, Talpaz M, Beran M, O'Brien SM, Rios MB, Stass S, Kantarjian HM (1995) Philadelphia chromosome-negative chronic myelogenous leukemia with rearrangement of the breakpoint cluster region. Long-term follow-up results. Cancer. 75:464–470

3. Hochhaus A, Kantarjian HM, Baccarani M, Lipton JH, Apperley JF, Druker BJ, Facon T, Goldberg SL, Cervantes F, Niederwieser D, Silver RT, Stone RM, Hughes TP, Muller MC, Ezzeddine R, Countouriotis AM, Shah NP (2007) Dasatinib induces notable hematologic and cytogenetic responses in chronic-phase chronic myeloid leukemia after failure of imatinib therapy. Blood. 109:2303–2309

4. Kantarjian HM, Giles F, Gattermann N, Bhalla K, Alimena G, Palandri F, Ossenkoppele GJ, Nicolini FE, O'Brien SG, Litzow M, Bhatia R, Cervantes F, Haque A, Shou Y, Resta DJ, Weitzman A, Hochhaus A, le Coutre P (2007) Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is effective in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase following imatinib resistance and intolerance. Blood. 110:3540–3546

5. Cortes JE, Kantarjian HM, Brummendorf TH et al (2011) Safety and efficacy of bosutinib (SKI-606) in chronic phase Philadelphia chromosome-positive chronic myeloid leukemia patients with resistance or intolerance to imatinib. Blood. 118:4567–4576

Cited by 20 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Ponatinib in the treatment of patients with chronic myeloid leukemia and increased cardiovascular risk: A review of management strategies;Hematology, Transfusion and Cell Therapy;2024-08

2. Exosomal miRNA‐21‐5p and miRNA‐21‐3p as key biomarkers of myocardial infarction;Health Science Reports;2024-07

3. Identification and characterization of a potent and selective HUNK inhibitor for treatment of HER2+ breast cancer;Cell Chemical Biology;2024-05

4. The molecular signature of BCR::ABL and BCR::ABL in a Drosophila melanogaster chronic myeloid leukemia model;iScience;2024-04

5. Management of cancer patients at high and very-high risk of cardiotoxicity: Main questions and answers;Current Problems in Cardiology;2024-03